What's happening?

The UK’s official exit from the EU on January 31st marked the start of a year-long transition period, with a temporary deal agreed with the EU to keep the terms of trade relatively stable, at least for now.

In recent years, there have been many changes within the pharmaceutical industry that have influenced a surge in demand for CDMOs.

A CDMO with inhalation development experience will understand the intricacies involved with and the unique requirements of the development pathway.

With a central focus on human safety, high quality standards for drug products are upheld worldwide through various drug agencies.

Understanding regional differences, implementing best-practice documentation processes key to successful approval outcomes 

Customers want us to keep control of any potential issues that can arise from the molecule – this demand comes from them and it has sometimes been a surprise when the molecule is already known. 

As pipelines expand and outsourcing manufacturing activity continues to increase, demand within the pharmaceutical industry is thriving. 

Quality by Design (QbD) allows for a systematic approach to drug development that is intended to improve quality by using analytical and risk-management methodologies for the design, development and manufacturing of new medications. The approach primarily aims to design quality into workflows from the outset.

With demand for CDMO services only set to grow in the coming years, the sector will continue to shape itself in order to meet the ever-evolving needs of developers.

Over the past decade the pharmaceutical industry has seen a surge in merger and acquisition (M&A) transactions. Among the several factors influencing consolidation, a primary driver of pharmaceutical M&A activity is the ability to minimise supply chain complexities. 

We have spent the last five years after the IPO building a global platform, getting a broad range of technologies and extending our customer base.